Scarica l'app Stockscreener
0.96
4.03%
0.0372
Dopo l'orario di chiusura:
.93
-0.03
-3.12%
Io Biotech Inc Borsa (IOBT) Ultime notizie
IO Biotech's Co-Founder Mads Hald Andersen Highlights Advances in Cancer Vaccine Research at 2025 AACR Annual Meeting - Nasdaq
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025 - The Globe and Mail
IO Biotech unveils promising vaccine preclinical data By Investing.com - Investing.com India
IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 - The Manila Times
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting - The Manila Times
New Cancer Vaccine Data Shows Powerful Immune Response in Multiple Tumors | IOBT Stock News - Stock Titan
Short Sellers Gave Up on These 3 Names Recently - The Globe and Mail
4 Cheap Stocks With Solid Fundamentals to Offset Market Uncertainty - The Globe and Mail
Cotton Extending Strength to Friday Morning - The Globe and Mail
Healthcare Services (HCSG) Receives a Hold from William Blair - The Globe and Mail
3 Reasons AMTM is Risky and 1 Stock to Buy Instead - The Globe and Mail
Nano One 2025 Annual General Meeting of Shareholders - The Globe and Mail
Boeing doesn't expect the US trade war with China to slow its recovery - The Globe and Mail
[WATCH] Trading Gaps: Spot Big Moves Before They Happen - The Globe and Mail
Limbach (LMB): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
Pre-market Movers: OPTN, WINT, AKBA, GCTK... - RTTNews
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC - The Globe and Mail
Viking Therapeutics Stock Pops But Struggles to Hold Gains - The Globe and Mail
CrowdStrike Stock is a Buy as Cyberthreat Environment Expands - The Globe and Mail
5 Top Psychedelic Stocks (2025) for Mental Health Investing - Securities.io
We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate - Yahoo Finance
Metastatic Melanoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Google (GOOGL) Offers U.S. Government Major Discounts as It Challenges Microsoft - The Globe and Mail
Seeking High Dividend Yield? Earn 9.6% from This Energy Stock Now. - The Globe and Mail
Tetra Tech Awarded £36 Million Multiple-Award Contract for Water Infrastructure Services - The Globe and Mail
NESR to Participate in Water Tower Research Fireside Chat on April 10 at 11am ET - The Globe and Mail
Financial Survey: Vistagen Therapeutics (NASDAQ:VTGN) versus IO Biotech (NASDAQ:IOBT) - Defense World
WSP Global Inc. (TSE:WSP) Receives C$284.85 Consensus Target Price from Brokerages - Defense World
Evergy, Inc. (NASDAQ:EVRG) Receives $69.08 Average Price Target from Brokerages - Defense World
Brokerages Set Aspen Aerogels, Inc. (NYSE:ASPN) PT at $19.11 - Defense World
Ag Futures Markets Are Suffering a Severe Case of Tariff Indigestion. When Will They Rebound? - The Globe and Mail
Prediction: This Artificial Intelligence (AI) Semiconductor Stock Could Start Soaring After April 16 - The Globe and Mail
Q1 Earnings Forecast for IO Biotech Issued By HC Wainwright - Defense World
Globus Medical acquires Nevro Corp. - Medical Buyer
Is Nvidia Stock a Buy or Sell Below $100 as a Global Trade War Escalates? - The Globe and Mail
IO Biotech (NASDAQ:IOBT) Given “Buy” Rating at HC Wainwright - Defense World
Fresh Quarter, Fresh Momentum? Markets Eye April 2nd Tariff Announcement - The Globe and Mail
IO Biotech Inc. (IOBT) reports earnings - qz.com
New PM2 Gene Discovery by Aurora Cannabis Enhances Disease Resistance - Securities.io
Alcon acquires majority stake in Aurion Biotech - Healio
IO Biotech secures over 400 million dkk in new capital - Dansk Industri
IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
IO Biotech Announces Acceptance Of Abstracts To Be Presented At The 2025 American Association For Cancer Research (AACR) Annual Meeting - MarketScreener
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Palantir Insiders including PLTR CEO Dump Shares as Valuation Skyrockets 340% - The Globe and Mail
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Globe and Mail
Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
TCEHY Earnings: Tencent Profits Leap on Gaming and Ads as Investors Wait on AI Returns - The Globe and Mail
IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025 - The Manila Times
IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025 - TradingView
Fast Company Names IO Biotech Top 10 Innovator for Cancer Vaccine Breakthrough - StockTitan
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
Partex and Fortress Biotech Announce Strategic - GlobeNewswire
IO Biotech (NASDAQ:IOBT) Upgraded at Piper Sandler - Defense World
Cancer Vaccines Market Analysis: Growth Drivers - openPR.com
Why BlackRock’s Panama Deal Highlights the Value of Real Asset ETFs - The Globe and Mail
Bavarian Nordic A/S – Notice Convening Annual General Meeting - Finansavisen
HC Wainwright Reiterates “Buy” Rating for IO Biotech (NASDAQ:IOBT) - Defense World
Promising Clinical Developments and Delayed Data Boost IO Biotech’s Buy Rating - TipRanks
Best Biotech Stocks to Buy in 2025 - The Motley Fool
Ratio Chart Of U.S. Dollar Index Against 10Y U.S. Notes Is Pointing Much Lower - The Globe and Mail
Melanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Melanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, - openPR
0.24%
36.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):